（编辑 楚丽君） 证券日报网讯 12月18日，新华制药在互动平台回答投资者提问时表示，2024年底公司于巨潮资讯网刊 发了《关于签署＜股权收购意向协议＞的公告》，涉及的产品为鱼油。目前无应披露而未披露重大信 息。 ...

华鲁集团旗下新华制药党委书记、董事长贺同庆上台领奖并代表获奖企业交流发言。他表示，新华制药将认真贯彻本 次大会精神，坚守初心、责任至上，积极完成华鲁集团的"十五五"战略部署，加快打造世界一流制药企业，为质量强 省、医药产业发展与人民健康事业做出更大贡献。（扈艳华） 之后，山东省政府为获得第五届中国质量奖的山东省1个单位，获得第十届山东省省长质量奖的5个单位、5名个人颁 奖。 12月15日，山东省质量大会在济南召开，山东新华制药（000756）股份有限公司（以下简称"新华制药"）荣获山东省 省长质量奖。 会上，省委副书记、省长周乃翔指出，质量事关经济社会高质量发展，事关人民生活品质和民生福祉。要把质量工作 摆在更加突出位置，加快建设质量强省，为奋力谱写中国式现代化山东篇章提供坚实质量支撑。同时，他还强调，要 在提高供给质量上持续加力，加强产业链质量一致性管控，提升产品、工程、服务质量水平。要在强化标准引领上持 续加力，加强标准创新、标准应用和标准制度型开放。要在夯实质量基础上持续加力，建强质量技术平台，推动资源 开放共享。要在塑强区域品牌上持续加力，深入实施"好品山东"品牌培育工程。要在加强质量监管上持续加力， ...

证券日报网讯 12月15日，新华制药在互动平台回答投资者提问时表示，根据信息披露公平性原则及相 关监管规定，公司会在定期报告中披露对应报告期末的股东人数信息。 （文章来源：证券日报） ...

Core Viewpoint - The evolution of the Shandong Quality Award reflects the economic transformation of Shandong Province from traditional industries to strategic emerging sectors [1][3]. Group 1: Changes in Award Management - The newly revised "Shandong Provincial Governor Quality Award Management Measures" limits the number of awarded enterprises and individuals, indicating a more meticulous approach to quality recognition [2]. - The evaluation criteria for the Governor Quality Award have become increasingly stringent, requiring applicants to have no major quality, safety, environmental, or public health incidents in the past three years [2]. Group 2: Industry Trends and Award Winners - The award winners indicate a shift from manufacturing to intelligent manufacturing, with a notable presence of technology-driven companies like Huaxi Biological, Shandong Guoci, and New Wind Light Electronics [3]. - The latest award cycle highlights a growing number of high-end manufacturing enterprises, such as Yantai Jereh Petroleum Equipment and Linyi Heavy Machinery, showcasing the province's industrial leadership [3]. - Award-winning companies are increasingly focusing on green and low-carbon transformations, exemplified by Zhongyu Food's large-scale biogas power generation project [3]. Group 3: Quality Development Strategy - The "14th Five-Year Plan for Quality Development in Shandong Province" sets ambitious goals, including the addition of over 20 Governor Quality Award enterprises and 300 new manufacturing champions [3]. - The emphasis on creating distinctive, scientifically advanced, and replicable quality management systems is crucial for companies competing for the award [5]. Group 4: Case Study - Xinhua Pharmaceutical - Xinhua Pharmaceutical, recognized for its historical contributions to the pharmaceutical industry, exemplifies the quality-driven approach that aligns with the province's economic transformation [4]. - The company has established a comprehensive quality assurance system compliant with cGMP standards, achieving multiple international certifications and awards [7]. - Xinhua Pharmaceutical's "Dual Full Six-Dimensional" quality management model emphasizes high-quality development across the entire industry chain and lifecycle, enhancing its competitive edge [8]. Group 5: Innovation and Market Position - Xinhua Pharmaceutical has a robust product portfolio, with significant market shares in key drug categories and a complete industry chain from fine chemical raw materials to active pharmaceutical ingredients [9]. - The company has achieved record highs in patent applications and approvals, indicating a strong focus on innovation and technology reserves [9]. - Xinhua Pharmaceutical's international collaborations and compliance with global standards position it favorably in the competitive pharmaceutical market [10]. Group 6: Future Outlook - The recognition from the Governor Quality Award is seen as a starting point for Xinhua Pharmaceutical, with expectations for further contributions to the province's transition from a quality-driven to a brand-driven economy [11].

生意社12月03日讯 12月3日，新华制药(寿光)硫酸价格，明日计划上调20元/吨，98%酸1280元/吨，成交可商谈。 PriceSeek评析 C：升贴水，包括物流成本、品牌价差、区域价差等因素。 生意社12月03日讯 12月3日，新华制药(寿光)硫酸价格，明日计划上调20元/吨，98%酸1280元/吨，成交可商谈。 PriceSeek评析 硫酸，多空评分：1 硫酸，多空评分：1 文章显示新华制药计划于明日上调硫酸价格20元/吨，98%酸价格调至1280元/吨，反映出市场需求增强 或供应收紧的信号。该消息对硫酸现货价格构成直接利好，可能推动市场交易价格上涨。考虑到涨幅 (约1.56%)相对温和且可商谈，未达到重大影响程度，故评分为+1表示一般利好。 【大宗商品公式定价原理】生意社基准价是基于价格大数据与生意社价格模型产生的交易指导价，又称 生意社价格。可用于确定以下两种需求的交易结算价： 1、指定日期的结算价 2、指定周期的平均结算价 定价公式：结算价=生意社基准价×K＋C K：调整系数，包括账期成本等因素。 C：升贴水，包括物流成本、品牌价差、区域价差等因素。 文章显示新华制药计划于明日上调硫酸价格20元 ...

致：香港交易及結算所有限公司 公司名稱: 山東新華製藥股份有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 第 2 頁 共 10 頁 v 1.1.1 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00719 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 195,000,000 | RMB | | 1 RMB | | 195,000,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 195,000,000 | RMB | | 1 RMB | | 195,000,000 | | 2. ...

证券日报网讯 11月27日晚间，新华制药发布公告称，近日，公司收到国家药品监督管理局核准签发的 盐酸肾上腺素注射液（简称"本品"）《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性 评价。 （文章来源：证券日报） ...

本品主要适用于因支气管痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长 浸润麻醉用药的作用时间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。 格隆汇11月27日丨新华制药(000756.SZ)公布，公司收到国家药品监督管理局核准签发的盐酸肾上腺素 注射液（以下简称"本品"）《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the listing application of Acetate Prednisone, which is primarily used for allergic and autoimmune inflammatory diseases [1] Group 1: Product Approval - The approval notification for Acetate Prednisone indicates its potential market entry, which may enhance the company's product portfolio [1] - The drug is commonly used for conditions such as active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, and various adrenal cortical insufficiencies [1] - Acetate Prednisone is also utilized in the comprehensive treatment of certain infections, broadening its therapeutic applications [1]

Core Viewpoint - The approval of the acetate prednisolone by the National Medical Products Administration marks a significant development for the company, as it expands its product offerings in the treatment of various inflammatory diseases [1] Company Summary - The company, Xinhua Pharmaceutical, has received the approval for the acetate prednisolone chemical raw material drug listing application, which is primarily used for allergic and autoimmune inflammatory diseases [1] - The drug is currently utilized for conditions such as active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, neutropenia, various adrenal cortex insufficiencies, severe dermatitis, and acute leukemia, as well as in the comprehensive treatment of certain infections [1] Industry Summary - According to relevant statistics, the sales revenue of acetate prednisolone-related formulations in Chinese public medical institutions is projected to be approximately 100 million RMB in 2024 [1]